Viz.ai Collaborates with Hypertrophic Cardiomyopathy Association to Improve Care for Hypertrophic Cardiomyopathy Patients

Collaboration aims to accelerate speed to diagnosis and treatment of hypertrophic cardiomyopathy

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with the Hypertrophic Cardiomyopathy Association (HCMA), the preeminent organization improving the lives of those with hypertrophic cardiomyopathy (HCM), to support, educate and advance research for HCM.

Hypertrophic cardiomyopathy is the most commonly inherited cardiovascular disease and one of the leading causes of sudden cardiac death in people under age 35. Despite its serious nature, only 20% of the estimated one million people in the U.S. with HCM have been diagnosed.¹ HCM causes a person’s heart muscles to thicken, making it harder for their heart to pump blood. HCM is associated with increased risks of atrial fibrillation, mitral valve disease, and heart failure.²

"Thanks to our partnership with Viz.ai, we now have the opportunity to offer more support, advocacy, and education to patients, families, the medical community, and the public regarding hypertrophic cardiomyopathy," said Lisa Salberg, Founder and CEO of the HCMA. "Together, we can enhance the lives of individuals with HCM, prevent premature deaths, and advance global understanding. There have been significant advancements in treatment options for those with HCM in recent years, and our current challenge is to identify and provide access to these new life-improving treatments for those who have been misdiagnosed or undiagnosed."

It can take two to five years for patients to receive an HCM diagnosis after symptoms start. Viz has developed and deployed the first and only regulatory-cleared machine learning algorithm to detect signs of HCM on routine ecg’s and direct patients to the right specialists for the right treatment. Viz HCM has been shown to help expedite the process to 90 days, from initial AI-powered detection of suspected HCM to diagnosis confirmation.³ Viz.ai has also launched its HCM Education Series, educational webinars led by key opinion leaders, including HCM specialists and patient advocates.

“We're thrilled to collaborate with the HCMA and have a positive impact on HCM patient care by addressing the misdiagnosis, and even, underdiagnosis of this disease and the lengthy patient journey,” said Gad Sakin, Chief Product Officer at Viz.ai. “We hope that by identifying the disease earlier, we can enable patients with HCM to have a higher quality of life and help risk stratify patients early.”

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,600+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One^TM is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

About HCMA

The Hypertrophic Cardiomyopathy Association, HCMA, was founded in 1996 as an international resource for patients, families, and the medical community on matters of importance to the HCM community. HCM is a genetic heart muscle disorder affecting 1 in 250 people worldwide. The HCMA provides services to enhance understanding, provide support, foster research, ensure high-quality health care and support public policies of importance to the community. The HCMA maintains a network of 50+ HCMA Recognized Centers of Excellence for the treatment and management of HCM. The HCMA is a 501c(3) with offices in Denville, NJ, and online at www.4hcm.org. For more information, contact us at 973-983-7429.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613046344/en/